Sugi Predict

Sugi Predict / Compounds / SCHEMBL19014629

SCHEMBL19014629

SCHEMBL19014629

CCOP(=O)(CN1CCN(CC[C@H](CSc2ccccc2)NC(=O)OC(C)(C)C)CC1)OCC

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ BCL2L1 Q07817 3/20 0.38
▸ SIGMAR1 Q99720 3/20 0.36
▸ ATM Q13315 1/20 0.36
▸ DRD2 P14416 3/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ PPARG P37231 3/20 0.35
▸ PPARA Q07869 3/20 0.35
▸ SYK P43405 1/20 0.35
▸ CCR5 P51681 1/20 0.34
▸ CTSK P43235 2/20 0.34
▸ CTSS P25774 1/20 0.34
▸ HRH2 P25021 1/20 0.34
▸ HRH1 P35367 1/20 0.34
▸ BCL2 P10415 1/20 0.34
▸ PPARD Q03181 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22428836 0.93 ALDH1A1 (0.39) SIGMAR1ATMDRD2KDM4EALDH1A1
SCHEMBL19014884 0.93 BCL2L1 (0.38) BCL2L1SIGMAR1ATMDRD2KDM4E
SCHEMBL22428789 0.93 BCL2L1 (0.34) BCL2L1SIGMAR1ATMDRD2KDM4E
SCHEMBL22409431 0.91 SIGMAR1 (0.39) BCL2L1SIGMAR1ATMDRD2KDM4E
SCHEMBL22409429 0.91 SIGMAR1 (0.39) BCL2L1SIGMAR1ATMDRD2KDM4E
SCHEMBL22409442 0.89 ALDH1A1 (0.39) BCL2L1KDM4EALDH1A1
SCHEMBL22409444 0.89 ALDH1A1 (0.39) BCL2L1KDM4EALDH1A1
SCHEMBL19014810 0.88 CCR5 (0.38) BCL2L1ATMDRD2KDM4ECCR5
SCHEMBL30405219 0.85 ATM (0.42) BCL2L1SIGMAR1ATMDRD2KDM4E
SCHEMBL30405586 0.85 ATM (0.42) BCL2L1SIGMAR1ATMDRD2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11111259-B2 Acylsulfonamide derivatives for treating senescence-associated diseases and disorders UNITY BIOTECHNOLOGY, INC. (US) 2021-09-07 — — US disclosed
US-20200291050-A1 ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS UNITY BIOTECHNOLOGY, INC. 2020-09-17 — — US disclosed
WO-2017101851-A1 ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS UNITY BIOTECHNOLOGY, INC. (US) 2017-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11111259-B2 Acylsulfonamide derivatives for treating senescence-associated diseases and disorders ACAT1, ARSA, GLA BCL2L1 3463/4885SIGMAR1 4672/4885ATM 404/4885
US-20200291050-A1 ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS ACAT1, ARSA, GLA BCL2L1 3463/4885SIGMAR1 4672/4885ATM 404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.